Covariant | OS | DMFS | ||
---|---|---|---|---|
HR (95% CI) | P | HR (95% CI) | P | |
Univariate analysis | ||||
Gender (Female vs. Male) | 0.581 (0.255–1.326) | 0.197 | 0.641 (0.297–1.381) | 0.256 |
Age (≤ 50 vs. > 50) | 1.918 (0.789–4.663) | 0.151 | 2.060 (0.901–4.707) | 0.087 |
Family history of cancer (Y vs. N) | 1.041 (0.244–4.442) | 0.956 | 0.845 (0.200–3.566) | 0.818 |
Clinical stage (I-II vs. III-IV) | 34.361 (8.021–67.199) | < 0.001 | 19.200 (6.601–55.842) | < 0.001 |
Pathological classification (R vs. O) | 1.232 (0.166–9.145) | 0.838 | 1.211 (0.164–8.928) | 0.851 |
Fuhrman classification (I-II vs. III-IV) | 4.601 (2.023–10.464) | < 0.001 | 4.835 (2.265–10.318) | < 0.001 |
AGK expression (Low vs. High) | 14.518 (3.369–62.556) | < 0.001 | 11.028 (3.285–37.021) | < 0.001 |
Multivariate analysis | ||||
Clinical stage (I-II vs. III-IV) | 22.264 (4.944–50.248) | < 0.001 | 11.727 (3.804–36.151) | < 0.001 |
Fuhrman classification (I-II vs. III-IV) | 1.125 (0.483–2.620) | 0.785 | 1.428 (0.648–3.146) | 0.376 |
AGK expression (Low vs. High) | 7.492 (1.701–32.998) | 0.008 | 6.161 (1.801–21.070) | 0.004 |